Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing small molecule kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH) [4] - The company's lead product is IkT-001, a prodrug of imatinib mesylate, specifically targeting PAH [4] Leadership Appointment - David McIntyre has been appointed as Chief Financial Officer, effective April 14, 2025 [1] - McIntyre brings over two decades of executive experience in the life sciences sector, having held various C-suite roles in biotech and medical device companies [2] - His previous experience includes a nearly decade-long tenure as a Partner at Apple Tree Partners, a life sciences venture capital fund [2] Educational Background - McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, a Bachelor of Laws from the University of Technology, Sydney, and an MBA from Duke University's Fuqua School of Business [3] - He is a Certified Practicing Accountant and is admitted as a legal practitioner in New South Wales and the High Court of Australia [3]